Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL29253571 | 1.00 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL663144 | 1.00 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL9109080 | 1.00 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL3682796 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL9692462 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL204687 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL529510 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL2301332 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL9692471 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL29391563 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118765275-A | Process for preparing phenyl tetrahydrofuran compounds | 基因泰克公司 | 2024-10-11 | — | — | CN | claimed |
| WO-2024108774-A1 | METAL-CATALYZED DOUBLE HYDROBORATION OF NITROGEN HETEROCYCLICS | GUANGDONG TECHNION-ISRAEL INSTITUTE OF TECHNOLOGY (CN) | 2024-05-30 | — | — | WO | claimed |
| CN-116554185-A | Chiral spiro oxindole compound and preparation method thereof | 中国科学技术大学 | 2023-08-08 | — | — | CN | claimed |
| US-20250122160-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| CN-114174289-B | Benzotriazole derivatives | ＵＢＥ株式会社 | 2025-03-07 | — | — | CN | disclosed |
| US-20250059147-A1 | PROCESSES FOR THE PREPARATION OF PHENYLTETRAHYDROFURAN COMPOUNDS | GENENTECH, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| CN-118765275-A | Process for preparing phenyl tetrahydrofuran compounds | 基因泰克公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-118515541-A | Method for post-treatment of farnesyl acetone reaction liquid | 宁夏天新药业有限公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2024108774-A1 | METAL-CATALYZED DOUBLE HYDROBORATION OF NITROGEN HETEROCYCLICS | GUANGDONG TECHNION-ISRAEL INSTITUTE OF TECHNOLOGY (CN) | 2024-05-30 | — | — | WO | disclosed |
| CN-117447464-A | Method for producing optically active compound | 首日生物制药公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-115141233-B | Synthesis method of rhodium bis (1, 5-cyclooctadiene) triflate | 浙江微通催化新材料有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-116829555-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116554185-A | Chiral spiro oxindole compound and preparation method thereof | 中国科学技术大学 | 2023-08-08 | — | — | CN | disclosed |
| CN-115141233-A | Synthesis method of bis (1, 5-cyclooctadiene) rhodium trifluoromethanesulfonate | 浙江微通催化新材料有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-114174289-A | Benzotriazole derivatives | 宇部兴产株式会社 | 2022-03-11 | — | — | CN | disclosed |
| EP-2855413-B1 | CATALYSTS AND PROCESSES FOR PREPARING ALDEHYDES | EASTMAN CHEM CO (US) | 2018-07-25 | — | — | EP | disclosed |
| US-9029544-B2 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-12 | — | — | US | disclosed |
| EP-2536733-B1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-20130053404-A1 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | US | disclosed |
| US-20120046304-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059147-A1 | PROCESSES FOR THE PREPARATION OF PHENYLTETRAHYDROFURAN COMPOUNDS | DHFR, DPYD, MTHFD2 | GPR3 4835/4885CA1 4638/4885CA2 4792/4885 |
| US-20250122160-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | GPR3 4163/4885CA1 4547/4885CA2 2713/4885 |
| US-20130053404-A1 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | CETP, MTTP, CES1 | GPR3 2442/4885CA1 4074/4885CA2 2423/4885 |
| US-20120046304-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | CETP, MTTP, CES1 | GPR3 2442/4885CA1 4074/4885CA2 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.